SCHEMBL6873281

SCHEMBL6873281

CC(C)(CO)CN1C(=O)N(Cc2ccc(-c3ccc4c(c3)CN(C3CC3)C4=O)cc2)C(C)(C)C1=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.34
ADRA1A P35348 1/20 0.34
HRH1 P35367 1/20 0.34
MCHR1 Q99705 1/20 0.34
MAOA P21397 2/20 0.33
GRM5 P41594 1/20 0.33
GRM1 Q13255 1/20 0.33
IKZF1 Q13422 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
GSPT1 P15170 1/20 0.31
CYP2C19 P33261 1/20 0.31
KCNH2 Q12809 1/20 0.31
DDB1 Q16531 1/20 0.31
CRBN Q96SW2 1/20 0.31
HDAC4 P56524 1/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12019504 0.88 CYP2C9 (0.36) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL1815304 0.86 GRM5 (0.36) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL6872988 0.83 GRM5 (0.35) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL6877162 0.83 CYP2C9 (0.38) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL1815874 0.82 IKZF1 (0.38) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL6873244 0.82 LIPG (0.38) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL6872946 0.82 PRF1 (0.34) KCNH2PRMT5WDR77
SCHEMBL6872983 0.81 RORC (0.35) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL12004508 0.79 CYP2C9 (0.34) CYP2C9ADRA1AHRH1MCHR1MAOA
SCHEMBL1817330 0.79 CYP2C9 (0.39) CYP2C9ADRA1AHRH1MCHR1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-8507521-B2 Heterocyclic derivatives Merck Sharp + Dohme B.V. (NL) 2013-08-13 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
US-20120220622-A1 HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME B.V. (NL) 2012-08-30 US disclosed
WO-2011051490-A2 HETEROCYCLIC DERIVATIVES N.V. ORGANON (NL) 2011-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220622-A1 HETEROCYCLIC DERIVATIVES GRIN2C, GRIN3A, GRIN2D CYP2C9 569/4885ADRA1A 715/4885HRH1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.